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Abstract
Background: Polycystic ovary syndrome (PCOS) affects up to 20% of women and is characterised by higher amounts
of visceral fat, obesity, insulin resistance, dyslipidemia and reproductive and cardiometabolic complications. Increased
oxidised low-density lipoprotein (LDL) concentrations have been associated with an increased risk of cardiovascular
disease (CVD)-related events. Oxidised LDL is rarely used as a marker for CVD risk in PCOS-related studies despite its
widely accepted role in atherogenesis and the increased risk factors associated with PCOS. Additionally, prolonged
periods of sedentary behaviour can negatively affect metabolic health. No studies have specifically examined the
effects of reducing sedentary behaviour on CVD risk in PCOS with a lifestyle physical activity intervention. The aim of
the current study is to measure the feasibility of a randomised controlled trial (RCT) examining the effects of supervised
exercise and reducing sedentary behaviour in women with PCOS on CVD risk.
Methods/design: A feasibility, exploratory RCT will be conducted. Fifty-one pre-menopausal females will be randomly
allocated between an exercise group (EG), a lifestyle physical activity group (LPAG) and a control group. Participants in
the EG will undertake a 12-week supervised aerobic exercise programme. The LPAG will aim to increase daily physical
activity and reduce sedentary behaviour for 12 weeks. The control group will not take part in any intervention. Primary
outcomes are feasibility and acceptability of the intervention and procedures. Secondary outcomes are oxidised LDL,
aerobic fitness, blood lipid profile, fasting glucose and insulin, testosterone and inflammatory markers.
Discussion: PCOS is associated with various increased risk factors for CVD, including hypertension, dyslipidemia,
abdominal obesity, insulin resistance, and inflammation. Whether oxidised LDL has a role in this increased risk is
not yet known. The present study aims to measure the feasibility of implementing structured exercise training
and/or increased lifestyle physical activity in women with PCOS, so that a subsequent adequately powered RCT
can be designed. The results from the study will be used to refine the interventions and determine the acceptability of
the study design. A limitation is that some self-monitoring in the lifestyle physical activity group may not be reliable or
replicable, for example inputting information about time spent cleaning/gardening.
Trial registration: ClinicalTrials.gov, NCT03678714. Registered 20 September 2018.
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Background
Polycystic ovary syndrome (PCOS) is the most common
endocrine disorder of reproductive age, affecting 15–20%
of women [1]. The diagnostic ‘Rotterdam’ criteria state
that women must present with two of the following three
signs/symptoms—hyperandrogenism, chronic anovula-
tion/oligomenorrhea, and polycystic ovaries—in the ab-
sence of other diseases that promote these symptoms [2].
PCOS is characterised by higher amounts of visceral fat,
obesity, and insulin resistance [3] and associated with re-
productive and cardiometabolic complications [4].
Dyslipidemia is prevalent in up to 70% of women with
PCOS [5]. The lipoprotein profile of women with PCOS
is characterised by elevated plasma triglycerides (TG)
and reduced high density lipoprotein (HDL) concentra-
tions [6]. Women with PCOS are at increased risk of
cardiovascular disease (CVD) compared with weight-
matched counterparts. Given the large proportion of
lean and overweight women who are affected by PCOS,
it is prudent to examine how CVD risk can be mitigated
in this high-risk population. Structured exercise has a
positive impact on women with PCOS and programmes
of 12 to 24 weeks can improve ovulation rates and insu-
lin sensitivity, and aid weight loss [3].
To our knowledge, no studies have examined the im-
pact of lifestyle physical activity and reducing sedentary
behaviour on CVD risk in women with PCOS. In
addition, oxidised low-density lipoprotein (LDL) is rarely
used as a marker for CVD risk in PCOS-related studies
despite its widely accepted role in atherogenesis.
Increased oxidised LDL concentrations have been associ-
ated with an increased risk of CVD-related events and
have been shown to accurately predict coronary artery
disease [7–9]. Total cholesterol:high-density lipoprotein
(TC:HDL) ratio and abdominal obesity are both posi-
tively correlated with oxidised LDL [7, 10]. Hence, con-
sidering the high prevalence of dyslipidemia and visceral
fat in PCOS populations, they may have a higher risk for
elevated oxidised LDL concentrations.
Additionally, research pertaining to the cardiometa-
bolic profile in women with PCOS has often produced
inconsistent results, possibly due to the wide range of
PCOS phenotypes possible once classified by the Rotterdam
criteria [11]. Phenotypes that present with hyperandrogen-
ism have been shown to have a worse metabolic profile and
increased cardiovascular risk factors than other phenotypes,
despite comparable distributions of body weight [11].
Regardless, there are no specific guidelines for this higher
risk phenotype.
Finally, recent research has emphasised that even when
adults meet physical activity guidelines of 150min/week
[12], prolonged periods of sedentary activity still negatively
affect metabolic and general health [13, 14]. High levels
of sedentary behaviour promote hyperinsulinemia and
subsequently affect insulin sensitivity and glucose con-
centrations [13], and as such sedentary behaviour may
be an exacerbating factor of PCOS.
Before an adequately powered RCT measuring the
effects of exercise and/or increased lifestyle physical
activity on such indicators of cardiovascular health can
be designed, the interventions must be refined and a
sample size must be calculated.
Therefore, the specific aims of the present feasibility
study are the following:
1. Assess the feasibility of conducting a randomised-
controlled trial (RCT) of exercise training and
increased physical activity in women with PCOS
2. Identify the use of partitioning participant data by
androgen profile
3. Measure rates of recruitment and retention
4. Measure rates of attendance and compliance with
the supervised exercise programme
5. Conduct post-intervention interviews with
completers and dropouts to refine the interventions
and assess barriers to physical activity, and how
they can influence future exercise interventions in
women with PCOS
6. Obtain a standard deviation for oxidised LDL so
that a sample size for a future, larger-scale RCT can
be calculated
Methods/design
Study design
This study is a feasibility study involving an exploratory
RCT. Fifty-one adult females with PCOS who are aged
18 years or over and pre-menopausal will be randomly
assigned to a 12-week exercise intervention, an increased
lifestyle physical activity group, or a control group. Out-
comes will be measured pre- and post- intervention.
Interview sessions will be undertaken with a proportion
of participants at the end of the trial to provide qualita-
tive information regarding barriers and facilitators to in-
creased physical activity. The study is being conducted
at the Centre for Sport and Exercise Science (CSES),
Sheffield Hallam University, Sheffield, UK. Sheffield
Teaching Hospitals, Sheffield, UK, will be used as a par-
ticipant recruitment centre.
The study duration is from September 2018 up to May
2021 and is sponsored by CSES, Sheffield Hallam
University.
Recruitment of participants
Participants will initially be screened according to inclu-
sion criteria by a clinical member of the research team via
a computerised search of their notes. Afterwards potential
participants will be sent information packs about the re-
search, including an invitation letter and participant
Woodward et al. Trials          (2020) 21:101 Page 2 of 8
information brochure. Email and contact information for
the researcher will be included in the packs and potential
participants will be given a minimum of 24 h and a max-
imum of 14 days to respond. It will be clearly stated in the
invitation letter that there is no obligation or pressure to
participate in the study and that if patients do not wish to
participate, their future medical care will not be
jeopardised.
Volunteers wishing to participate in the study will be
requested to contact a member of the research team or
respond via letter by a specified date. Participants who
respond to the letter of invitation and satisfy triage
through telephone pre-screening will be invited into
CSES of the Sheffield Hallam University for their initial
session, where they will provide written informed con-
sent and have an opportunity to familiarise themselves
with the protocol and ask questions. They will then
undertake baseline assessments.
It will be assumed that those who haven’t contacted
the research team could still potentially have an interest
in study participation but may be too busy to respond.
They will be re-contacted via telephone (or sent a
follow-up letter if telephone contact cannot be estab-
lished) to remind them of the invitation to the study.
Potential participants who decline to volunteer or who
do not respond to the follow-up letter will not be
contacted further, since it will be assumed that they do
not wish to participate in the study.
Eligibility criteria
Participants eligible for the trial must meet the below
inclusion criteria as follows:
i) Women diagnosed with PCOS according to the
Rotterdam criteria 2003, National Institute of
Health (NIH) 1990 criteria or Androgen Excess and
Polycystic Ovary Syndrome (AE-PCOS) Society
2006 criteria
ii) Have experienced menarche (their first menstrual
bleeding) and be at least 18 years of age
iii) Are English speaking
iv) Are physically able to perform exercise
Exclusion criteria include:
i) Post-menopausal status
ii) Are smokers
iii) Are undertaking regular structured exercise defined
as > 150 min/week
iv) If taking metformin, have been taking it for < 3months
v) Are taking the oral contraceptive pill (OCP) or have
taken it in the last month
vi) Have any medical condition that may be
responsible for the symptoms of PCOS, such as
congenital hyperplasia, androgen-secreting tumour,
hyperprolactinemia, or Cushing’s syndrome
vii) Have current, clinically defined CVD or a history of
cardiac events
Participants will be advised that commencement of
any of the above-mentioned medications during the trial
is a contraindication and they will be withdrawn from
the trial.
Baseline and post-intervention measurements
During visit 1, after written informed consent has been
obtained and eligibility confirmed by AW, the following
baseline tests measurements will be made: age, an-
thropometric measures (stature, body mass, hip and
waist measurements), finger-prick and venous blood
sampling (see Outcome measures for a detailed descrip-
tion of analytes), aerobic fitness assessed by the Astrand-
Rhyming single stage test (see Outcome measures for
detailed description).
After completion of the intervention, all tests and
measurements will be repeated.
Randomisation and masking
Participants will be randomised in equal numbers between
a supervised exercise programme, a lifestyle physical activ-
ity group and a control group. This will be undertaken
using a computerised randomisation programme (Quick-
Calcs, GraphPad Software, USA) by an experienced re-
searcher who is not involved in the study assessments.
Allocation will be placed in sequentially labelled opaque
envelopes. Each envelope will be offered to the partici-
pants, in sequence, by the chief investigator, on comple-
tion of their baseline assessments. It is not possible to
mask participants or research team to the allocated inter-
vention. Outcome assessors will be blinded to group allo-
cation for anthropometric and fitness measures, but blood
assays will be carried out by the same member of the
research team. This is because blood assays are not
considered to be subjective and are unlikely to be affected
by outcome assessor bias.
Withdrawals
Participants may withdraw at any time without providing
a reason. They may also choose to withdraw their data
from the study. A participant will be considered to be
withdrawn if they request to leave the trial or they are
lost to follow-up. If allocated to the exercise group,
participants will be considered as withdrawn if they no
longer attend the supervised exercise sessions, and in
the lifestyle physical activity group if they no longer
monitor daily physical activity through the fitness appli-
cation. Data from withdrawn participants will not be
used; only data from participants who completed the
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intervention and baseline and post-intervention assess-
ments will be used in analysis.
Harms and auditing
Adverse events will be collected, reported and assessed
by the research team to determine severity and whether
they are likely to be serious adverse events due to the
trial. Serious adverse events and reactions will be reported
to the relevant ethics committees and appropriate action
taken, if any. Auditing will be carried out by the sponsor,
Sheffield Hallam University. In the event of harm to
participants arising as a result of the management, design
or conduct of the research, Sheffield Hallam University
insurance and indemnity policies will apply.
Supervised exercise programme
Participants assigned to the exercise group will be in-
vited to undertake two sessions of supervised exercise
training each week for 8 consecutive weeks and three
sessions of supervised exercise training each week for
the final 4 consecutive weeks at CSES at Sheffield
Hallam University. Each session will last approximately
60 min and will involve 40 min of an individualised exer-
cise protocol performed either on a cycle ergometer or a
motorized treadmill preceded by a 10min warm-up and
followed by a 10 min cool down.
The duration and intensity of the programme was se-
lected based on evidence from exercise trials in PCOS
that have identified that supervised, moderate-intensity
exercise sessions between 50 and 70% VO2max for a
minimum of 12 weeks showed improvement in cardio-
metabolic risk factors such as TG, inflammation, and in-
sulin resistance [3, 4, 15, 16].
Most of these studies involved three sessions per week
[3, 15, 16]. However, to maximise adherence and reduce
inconvenience to participants, the current trial com-
prises two sessions per week, at a duration of 1 h, in-
creasing to three sessions per week for the final 4 weeks.
Various research studies have shown that two sessions
per week for 8 weeks can elicit improvements in micro-
vascular endothelial function and exercise tolerance,
both of which can reduce cardiovascular disease risk
[17, 18], which is regarded as a key outcome in the
current study. Additionally, the American College of
Sports Medicine (ACSM) recommends a weekly dur-
ation of 60–150 min of exercise duration for inactive
individuals or individuals who do not participate in
any habitual physical activity [19].
ACSM’s Frequency, Intensity, Time and Type (FITT)
principle recommends increasing one variable of the
principle after at least one month of exercise. Extremely
deconditioned to moderately deconditioned individuals
are recommend to work at a moderate intensity of ~
57–74% HRmax, which correlates with previous exercise
interventions in PCOS where workload is set to a
VO2max of 50–70% [19]. The programme therefore in-
creases in intensity at increments of 4 weeks up to 74%
HRmax, allowing for progression while remaining moder-
ate in effort and within the recommendations for moder-
ately deconditioned individuals.
In order to calculate individual heart rate zones for
each participant, a formula (206.9 − (0.67 × age)) will be
used to calculate maximum heart rate [19]. Participants
will wear a Polar T31 heart rate monitor chest strap and
wristwatch for the duration of each session in order to
monitor their heart rate and stay in the assigned zones.
Lifestyle physical activity group
Participants randomized to the lifestyle physical activity
group will attend CSES at Sheffield Hallam University
for all the tests and measurements but will not take part
in the structured exercise intervention. However, advice
and information on how to increase physical activity will
be provided using British Heart Foundation guidelines:
‘Get active, stay active’. This will be discussed during the
informed consent consultation. Participants will be asked
to monitor and track their daily physical activity using a
smartphone fitness application. This will either be Google
Fit or Apple Health, since these are the default fitness
apps for Android and Apple phones and are often pre-
installed. The research team will gain permission to access
their recorded activity. Between the baseline measure-
ments and those after 12 weeks, participants will receive
regular telephone support, approximately once a week, to
obtain information about their progress and provide ad-
vice as needed.
Participants in the control group will not undertake
any intervention but will still receive standard care from
their medical professional which may include general
weight-loss advice. To improve adherence for the con-
trol group, the research team will offer all participants
allocated to the group the opportunity to undertake
supervised exercise sessions at the CSES after their
successful completion of the trial.
Participant timeline
The Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) (Additional file 1) diagram
shown in Fig. 1 outlines the participant schedule of enrol-
ment, intervention, close-out and assessment time-points.
Outcome measures
Feasibility outcomes
The primary outcomes for this study are acceptability
and feasibility of procedures for recruitment, allocation,
measurement, and retention for the intervention proce-
dures. Recruitment rate will be calculated by dividing
the number of women eligible and consenting by the
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recruitment period. Attrition rates will be established as
discontinuation of the intervention and loss to follow-up
measurement for both conditions. Compliance will be
monitored by session attendance and monitoring the
data from recorded daily physical activity, with examin-
ation of reasons for drop-out or non-compliance. Reasons
for drop-out will also be used to assess the suitability of
allocation procedures. Suitability of measurement proce-
dures will be evaluated by completion rates and reasons
for missing data. The post-intervention interview will be
used to assess the acceptability of the exercise programme
and lifestyle physical activity group intervention, along
with attendance and compliance data.
Secondary outcomes
Serum oxidised LDL is the secondary outcome of the
current study and will be analysed by enzyme-linked
immunosorbent assay (ELISA). Optical density will be
measured using an electronic plate reader and can be
used to determine the quantity of the specific antigen in
the blood using a calibration curve.
ELISA will also be used for quantitative analysis of C-
reactive protein, neopterin, TBARS, fasting insulin and
sex hormone binding globulin (SHBG). Free testosterone
will be measured using a liquid chromatography method.
This method has been chosen due to its ability to detect
small amounts of serum testosterone, particularly in
lower concentrations in females [20]. Free testosterone
will be quantified using a calibration curve and calculat-
ing peak area.
Aerobic fitness will be assessed using the Astrand-
Rhyming test. This is a submaximal single-stage test per-
formed on a cycle ergometer, lasting between 6 and 7
min [21]. The goal is to obtain heart-rate values between
125 and 170 beats per minute (bpm) for a given work-
rate at 50 revs/minute (50 or 75 watts for unconditioned
women) [21]. Heart rate is then measured at the fifth
and sixth minute if steady state (a difference ≤ 5 bpm is
STUDY PERIOD
Enrolment Allocation
Post-allocation Close-
out
TIMEPOINT -1 wk 0 1 wk
2 
wk
3 
wk
4 
wk
5 
wk
6 
wk
7 
wk
8 
wk
9 
wk
10 
wk
11 
wk
12 
wk
+2 wk
ENROLMENT:
Eligibility screen X
Informed consent X
Allocation X
INTERVENTIONS:
Exercise Group
Lifestyle Physical 
Activity Group
Control Group]
ASSESSMENTS:
Aerobic fitness, 
oxidized LDL, 
blood lipids, 
testosterone, 
glucose, SHBG
X
X
Interview
X
Fig. 1 Participant schedule of enrolment, interventions and assessments
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achieved), and the average of the two heart-rate mea-
surements can be used to estimate VO2max according to
a nomogram. This value must be adjusted for age to
account for decreasing maximal oxygen uptake and
maximal heart rate with age [19].
For lipid profile (including LDL-cholesterol, HDL-
cholesterol, TG and TC) and fasting glucose, a Choles-
tech Automated Analyser will be used. A fingerprick
blood sample is obtained and collected into a capillary
tube. The sample is then inserted into the machine cas-
sette. This produces an automated reading from the
sample in which accuracy can be maintained by using
control samples and calibrations. HDL sub-fractions will
be measured using gel electrophoresis.
In order to measure the amount of lifestyle physical
activity (and subsequent sedentary activity), the long-form
International Physical Activity Questionnaire (IPAQ) will
be administered at baseline and post-intervention to all
participants. This will be used to compare differences in
time spent sitting, both during the week and weekend,
and the amount of lifestyle physical activity (including
transport, housework, and leisure time) undertaken.
Waist circumference will be measured with the partici-
pant standing with feet together, and the tape measure
placed around the narrowest part of the torso, between
the umbilicus and the xyphoid process [19]. Hip circum-
ference will be measured with the participant standing
as above, and the tape measure placed around the max-
imum circumference of the buttocks [19].
Blood sampling and storage
Blood will be drawn from participants on their initial
and post-intervention visit to the CSES, by a member of
the research team trained in venepuncture. Blood sam-
ples will be centrifuged and serum aliquoted and stored
at − 80 °C until they are analysed.
Assays will be performed at the Biomolecular Research
Centre, Sheffield Hallam University, by a member of the
research team.
Data collection, monitoring, management and storage
Data will be collected by the chief investigator (AW)
using data collection forms and entered into a compu-
terised database. Range checks will be carried out to en-
sure data quality. Data checks will frequently be
completed by other members of the research team.
Participants’ names will be anonymised and replaced
with a code using a computerised pseudonymisation
programme (Open Pseudonymiser, University of
Nottingham, UK). All other study data will be stored
securely on Sheffield Hallam University premises
and/or saved on encrypted computer drives on site.
Only the research team will have access to the data,
including the final trial dataset. Data will be securely
archived after study closure and stored for up to 7 years,
when it will be destroyed. All data will be stored and man-
aged according to Sheffield Hallam University’s confiden-
tiality and data protection policies.
Due to the low risk involved in this study, no formal
data monitoring committee will be formed. However,
the study will be regularly monitored by the research
team members being led by a senior team member (MK)
who will meet at regular intervals throughout the study
period.
Interview and qualitative methods
After trial completion, four participants from each
group, as well as drop-outs, will be offered the oppor-
tunity to complete a semi-structured interview either in
person or over the telephone with a member of the re-
search team. All interviews will be recorded with an
audio recording device and then transcribed verbatim.
The interview will explore their opinions and experi-
ences of the intervention, and factors that may be a bar-
rier or facilitator to physical activity in the future. It will
also assess the acceptability of the exercise intervention
and study procedures, to refine the design and delivery
of the exercise programme for the RCT, and will last ap-
proximately 45 min.
Interviews will allow the exploration of participant’s
motivations, attitudes and experience in detail and
within their personal frame of reference. This will be
useful because of the wide-ranging symptoms of PCOS,
which may affect individuals in a variety of ways that are
not necessarily uniform across all participants. Tran-
scripts will be analysed using thematic analysis [22].
Thematic analysis is an inductive method for identifying,
analysing and reporting patterns within data. As such, it
allows for a great deal of flexibility in analysing qualita-
tive data because it is independent of theory and epis-
temology; rather, it can be applied across a range of
theoretical approaches [22]. This allows for themes and
patterns to be identified by the researcher without trying
to fit it into a pre-existing coding frame, and is therefore
considered to be data-driven and accessible [22].
Data analysis
All quantitative measurements will be presented as
mean ± standard deviation (SD) unless otherwise stated.
As this is a feasibility study, no formal sample size cal-
culation was required. The sample size for a feasibility
study needs to strike a balance where it does not cause
undue burden on participants by being too large, but
not be too small that critical parameters (such as con-
sent rate, attrition, and compliance) cannot be precisely
estimated and used for the calculation of a full-scale
RCT. It has been posited that a rule of thumb of at least
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30 participants overall should be sufficient for a feasibil-
ity trial [23].
Additionally, sample sizes between 24 and 50 have
been recommended to calculate a standard deviation
of an outcome that can then be entered into a formal
power calculation for the full-scale RCT [24, 25]. Oxi-
dised LDL concentrations are a secondary outcome
for the proposed study, and a sample size within this
remit will provide a reliable standard deviation for
oxidised LDL to be used in a power calculation. Since
there are three groups, a total sample size of 51 will
allow even numbers across three groups (17 in each
group).
Descriptive statistics will be used to characterise the
groups at baseline and post-intervention. Pre and post-
intervention means will be recorded for each group. Dif-
ference between means will be assessed using two-factor
mixed-ANOVAs where the effect of two independent
variables (grouping and time point) will be measured on
the dependent variables. The within-subjects factor is
time, and the between-subjects factor is group. Post-hoc
analysis will be undertaken in the event of any signifi-
cant differences in group means. Data will be assessed to
ensure the assumptions of the mixed-ANOVA are met
including checks for normality.
Using free-testosterone data, all participants will be
categorised by androgen profile as normo-androgenic or
hyper-androgenic based on laboratory cut-off values
[26]. Androgen profile will then be added into the
mixed-ANOVA model, where time and androgen profile
will be the within-subjects factors and group will be the
between-subject factor. Partial eta squared will be pre-
sented. Assuming normality, Pearson correlation coeffi-
cient will be used to analyse the bivariate correlation
between variables. Results of all analyses will be inter-
preted with a caveat that the study is a feasibility trial
without a formal sample size calculation and as such
may be inadequately powered. All statistical analysis will
be undertaken using the latest IBM SPSS Statistics soft-
ware, currently version 24.0.
Dissemination
Trial participants will be informed of the results of the
study via a summary report. The results will be dissemi-
nated at conferences and through journal publications.
Relevant UK PCOS charities will be informed of results
in laymen’s terms. No later than 3 years after study clos-
ure, an anonymised participant-level dataset will be
deposited in an appropriate data archive for sharing
purposes. Neither the results of the study nor any infor-
mation provided by participants or the sponsor for study
purposes will be passed on to any third party without
consent from the participants and sponsor.
Discussion
Oxidised LDL has been associated with all stages of ath-
erosclerosis, as well as other conditions linked to CVD,
such as diabetes mellitus and metabolic syndrome [27].
PCOS is associated with various increased risk factors
for CVD, including hypertension, dyslipidemia, abdom-
inal obesity, insulin resistance, inflammation, and endo-
thelial dysfunction [3, 6]. Whether oxidised LDL has a
role in this increased risk in PCOS is not yet known.
The present study aims to measure the feasibility of
implementing exercise training and/or a lifestyle physical
activity intervention in women with PCOS. This will
provide necessary information to design an adequately
powered RCT examining the effect of such interventions
on oxidised LDL and CVD risk. The strengths of this
study include the lifestyle physical activity arm, which
will encourage participants to be more active whilst re-
ducing time spent sedentary, and monitor their daily
physical activity, so that the effects of this can be com-
pared with a formal, structured exercise programme.
Additionally, partitioning data by androgen profile will
highlight differences in normo- and hyper-androgenic
cardiometabolic profiles and how exercise and physical
activity can impact these. This study aims to provide
feasibility data and effect sizes in order to plan for a full-
scale RCT. In addition, it aims to contribute to recommen-
dations that move away from a one-size fits all approach to
PCOS management and move to recommendations based
on individual presentations of the condition. A limitation is
that some self-monitoring in the lifestyle physical activity
group may not be reliable or replicable, for example input-
ting information about time spent cleaning/gardening.
Trial status
Protocol version 6.0; 6 September 2018. Recruitment
beginning October 2018 until required numbers are
reached.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3962-7.
Additional file 1. Populated SPIRIT checklist.
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